Factors influencing the outcome of vedolizumab treatment: Real‐life data with objective outcome measurements
| العنوان: | Factors influencing the outcome of vedolizumab treatment: Real‐life data with objective outcome measurements |
|---|---|
| المؤلفون: | Luc Biedermann, Valérie Pittet, Orla Mader, Nadine Zahnd‐Straumann, Pascal Juillerat, Gerhard Rogler, Petr Hruz, Frank Seibold, Pierre Michetti |
| المساهمون: | University of Zurich, Seibold, Frank |
| المصدر: | United European Gastroenterology Journal United European gastroenterology journal, vol. 9, no. 3, pp. 398-406 |
| بيانات النشر: | John Wiley and Sons Inc., 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Male, anti‐TNF naive, Outcome (game theory), Inflammatory bowel disease, Cohort Studies, 0302 clinical medicine, Crohn Disease, Outcome Assessment, Health Care, Odds Ratio, Adult, Antibodies, Monoclonal, Humanized/therapeutic use, Biomarkers/analysis, Colitis, Ulcerative/drug therapy, Crohn Disease/drug therapy, Female, Gastrointestinal Agents/therapeutic use, Humans, Inflammatory Bowel Diseases/drug therapy, Leukocyte L1 Antigen Complex/analysis, Remission Induction, Steroids/therapeutic use, Tumor Necrosis Factor Inhibitors/therapeutic use, Crohn's disease, adverse events, anti-TNF experienced, anti-TNF naive, inflammatory bowel disease, real-life data, remission, safety, ulcerative colitis, vedolizumab, 610 Medicine & health, Gastroenterology, real‐life data, Ulcerative colitis, Real life data, 10219 Clinic for Gastroenterology and Hepatology, Oncology, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, 2730 Oncology, Original Article, Steroids, medicine.drug, medicine.medical_specialty, medicine.drug_class, anti‐TNF experienced, Monoclonal antibody, Antibodies, Monoclonal, Humanized, Vedolizumab, 03 medical and health sciences, Gastrointestinal Agents, Internal medicine, medicine, 2715 Gastroenterology, Adverse effect, business.industry, Inflammatory Bowel Disease, medicine.disease, Inflammatory Bowel Diseases, digestive system diseases, Colitis, Ulcerative, Tumor Necrosis Factor Inhibitors, business, Leukocyte L1 Antigen Complex, Biomarkers |
| الوصف: | Background Vedolizumab (VDZ), a humanised monoclonal antibody against a4ß7‐integrin, has shown efficacy in inflammatory bowel disease (IBD). It is of importance to assess the mid‐to long‐term efficacy of VDZ using real‐life data. Objective Our study aimed to determine the efficacy of VDZ in patients with IBD with and without prior exposure to anti‐tumour necrosis factor (TNF) treatments in a real‐life setting. Furthermore, we investigated confounding factors influencing the remission to VDZ. Methods Patients participating in the Swiss IBD Cohort Study were included in this study. Remission was defined as calprotectin less than 200 mg/kg stool and/or mucosal healing determined by endoscopy. End points were determined between Months 4 and 8 (T1) and between Months 12 and 16 (T2) after VDZ induction. Results Remission was reported in 50.5% (110/218) of patients in T1 (48.7% Crohn's disease [CD] and 52.5% ulcerative colitis [UC]) and 46.8% (102/218) in T2 (47% CD and 46.5% UC). In UC patients, a significantly higher remission rate was achieved in T2 among anti‐TNF‐naive patients (57.7%) compared to anti‐TNF‐experienced patients (34.7%; p = 0.02; odds ratio = 0.39, 95% confidence interval: 0.17–0.87). In patients with CD, no difference could be seen in either evaluation interval. Multivariable analysis showed that disease duration significantly influenced remission rates among UC patients. A late response to VDZ therapy with an achievement of remission in T2 was seen in a fifth of all patients (CD: 21.7%, UC: 20.8%). VDZ treatment was stopped in a third of all patients (31.8%) due to nonresponse, adverse events or aggravation of extra‐intestinal manifestations. Conclusion In a real‐life national cohort setting, VDZ induced remission in more than half of IBD patients. Previous treatment with anti‐TNF agents was associated with a significant lower efficacy of VDZ in UC but not in CD patients. |
| وصف الملف: | document7541.pdf - application/pdf; application/pdf |
| اللغة: | English |
| تدمد: | 2050-6414 2050-6406 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b391b467f60ffd025a3fc1291387626eTest http://europepmc.org/articles/PMC8259282Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b391b467f60ffd025a3fc1291387626e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20506414 20506406 |
|---|